Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT)
Name:
36351720.pdf
Size:
2.522Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Zhong, J.Brown, S.
Serra, Maria
Shuttleworth, P.
Bownes, P.
Thompson, C.
Reed, Rachel
Reeves, Kimberley
Dubec, Michael
McHugh, Damien
Eccles, Cynthia L
Chuter, Robert
Tsang, Y. M.
Taylor, N. J.
West, Catharine M L
Buckley, D.
Scarsbrook, A.
Choudhury, Ananya
Hoskin, Peter J
Henry, A.
Affiliation
Leeds Institute of Medical Research, University of Leeds, Leeds, UKIssue Date
2022
Metadata
Show full item recordAbstract
Introduction: Radiotherapy is the most common curative treatment for non-metastatic prostate cancer; however, up to 13% of patients will develop local recurrence within 10 years. Patients can undergo further and potentially curative treatment including salvage surgery, brachytherapy (BT), external beam radiotherapy, high-intensity focused ultrasound and cryotherapy. Systematic review shows that high-dose-rate (HDR) BT and stereotactic body radiotherapy (SBRT) have the best outcomes in terms of biochemical control and lowest side effects. The reirradiation options for previously irradiated prostate cancer (RO-PIP) trial aims to determine the feasibility of recruitment to a trial randomising patients to salvage HDR-BT or SBRT and provide prospective data on patient recorded toxicity outcomes that will inform a future phase III trial. Methods and analysis: The primary endpoint of the RO-PIP feasibility study is to evaluate the patient recruitment potential over 2 years to a trial randomising to either SBRT or HDR-BT for patients who develop local recurrence of prostate cancer following previous radiation therapy. The aim is to recruit 60 patients across 3 sites over 2 years and randomise 1:1 to SBRT or HDR-BT. Secondary objectives include recording clinician and patient-reported outcome measures to evaluate treatment-related toxicity. In addition, the study aims to identify potential imaging, genomic and proteomic biomarkers that are predictive of toxicity and outcome based on hypoxia status, a prognostic marker of prostate cancer.Citation
Zhong J, Brown S, Serra M, Shuttleworth P, Bownes P, Thompson C, et al. Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT). BMJ open. 2022 Nov 8;12(11):e068580. PubMed PMID: 36351720. Epub 2022/11/10. eng.Journal
BMJ OpenDOI
10.1136/bmjopen-2022-068580PubMed ID
36351720Additional Links
https://dx.doi.org/10.1136/bmjopen-2022-068580Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/bmjopen-2022-068580
Scopus Count
Collections
Related articles
- A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).
- Authors: Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, Reiter RE, Rettig M, Calais J, Nickols NG, Dess RT, Spratt DE, Steinberg ML, Nguyen PL, Davis BJ, Zaorsky NG, Kishan AU
- Issue date: 2021 Sep
- Salvage Reirradiation Options for Locally Recurrent Prostate Cancer: A Systematic Review.
- Authors: Zhong J, Slevin F, Scarsbrook AF, Serra M, Choudhury A, Hoskin PJ, Brown S, Henry AM
- Issue date: 2021
- Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
- Authors: Peyraga G, Lizee T, Khalifa J, Blais E, Mauriange-Turpin G, Supiot S, Krhili S, Tremolieres P, Graff-Cailleaud P
- Issue date: 2021 Jun
- Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
- Authors: Mbeutcha A, Chauveinc L, Bondiau PY, Chand ME, Durand M, Chevallier D, Amiel J, Kee DL, Hannoun-Lévi JM
- Issue date: 2017 Mar 9
- Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes.
- Authors: Cozzi S, Finocchi Ghersi S, Bardoscia L, Najafi M, Blandino G, Alì E, Augugliaro M, Vigo F, Ruggieri MP, Cardano R, Giaccherini L, Iori F, Botti A, Trojani V, Ciammella P, Iotti C
- Issue date: 2023 Jun